GBT Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Global Blood Therapeutics (GBT) announced its participation in upcoming investor conferences. The Bank of America Securities 2022 Healthcare Conference will take place in Las Vegas on May 11 at 2:40 p.m. P.T., and the RBC Capital Markets 2022 Global Healthcare Conference is set for New York on May 18 at 9:00 a.m. E.T. Both fireside chats will be available via live webcast on GBT's website, with replays accessible for a month after each event. GBT is focused on developing innovative treatments for sickle cell disease, including its FDA-approved drug Oxbryta.

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in fireside chats at the following investor conferences:

• Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, at 2:40 p.m. P.T.; and
• RBC Capital Markets 2022 Global Healthcare Conference in New York, NY on Wednesday, May 18, at 9:00 a.m. E.T.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

 

FAQ

When is GBT participating in investor conferences?

GBT will participate in the Bank of America Securities 2022 Healthcare Conference on May 11 and the RBC Capital Markets 2022 Global Healthcare Conference on May 18.

What time will GBT's fireside chats occur?

GBT's fireside chat at the Bank of America Securities Conference is at 2:40 p.m. P.T. on May 11, and at the RBC Capital Markets Conference at 9:00 a.m. E.T. on May 18.

Where can I watch GBT's investor conference webcasts?

The webcasts for GBT's investor conferences will be available live on their website in the Investors section.

What is the focus of Global Blood Therapeutics?

GBT is dedicated to developing treatments for sickle cell disease, including the FDA-approved drug Oxbryta.

What is the significance of Oxbryta in GBT's portfolio?

Oxbryta is the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, addressing the root cause of sickle cell disease.